Search Results 1241-1250 of 11244 for Antifungal Resistance

1. Ublituximab In Autoantibody Positive Immune Mediated Necrotizing Myopathy - Mayo Clinic

   Recent or ongoing bacterial, viral, or fungal infection requiring systemic treatment within 14 days of the time of informed consent. 8. Current suppressive ...

2. Connective Tissue Diseases - Mayo Clinic Healthcare

   Mayo Clinic Healthcare provides specialist assessment and treatment for connective tissue diseases using advanced testing and expert care.

3. KO-2806 Monotherapy And Combination Therapies In Advanced Solid Tumors - Mayo Clinic

   * Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy. * Inability to swallow, impairment of gastrointestinal (GI) ...

4. C Clinical Trials - Mayo Clinic Research

   The purpose of this study is to evaluate if Vancomycin Resistant Enterococci (VRE) can be eradicated in patients with Clostridium Difficile infection (CDI) ...

5. Trial Of Eflornithine Plus Sulindac In Patients With Familial Adenomatous Polyposis (FAP) - Mayo Clinic

   This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) ...

6. Study To Assess Anti-CD38 Antibody Drug Conjugate In Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   Active bacterial, viral, or fungal infection within 72 hours of the infusion of STI-6129; patients with ongoing use of prophylactic antibiotics, antifungal ...

7. Neoadjuvant Pembrolizumab - Mayo Clinic

   Active infection requiring antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient's ability to ...

8. A Study Of BBI608 Combined With Standard Chemotherapies In Adult Patients Who Have Pancreatic Cancer - Mayo Clinic

   Uncontrolled active infection including bacterial, viral or fungal requiring systemic therapy; Clinically significant non-healing or healing wounds ...

9. Clazakizumab For The Treatment Of Chronic Active Antibody Mediated Rejection In Kidney Transplant Recipients (IMAGINE) - Mayo Clinic

   History of or current invasive fungal infection or other opportunistic infection, including (but not limited to) the following: a nontuberculous ...

10. Study Of MK-3475 (Pembrolizumab) In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma After Treatment With Platinum-based And Cetuximab Therapy (MK-3475-055/KEYNOTE-055) - Mayo Clinic

    ... resistant (not responding) to both platinum and cetuximab; Available tissue for biomarker analysis; Measurable disease based on RECIST 1.1 as determined by ...